Astrana Health (NASDAQ:ASTH) Downgraded to “Hold” Rating by Wall Street Zen

Wall Street Zen cut shares of Astrana Health (NASDAQ:ASTH) from a buy rating to a hold rating in a report released on Sunday.

ASTH has been the topic of a number of other research reports. Truist Financial increased their price objective on shares of Astrana Health from $47.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, August 10th. TD Cowen lifted their target price on shares of Astrana Health from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Weiss Ratings upgraded shares of Astrana Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 1st. BTIG Research increased their price target on Astrana Health from $50.00 to $65.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Finally, Needham & Company LLC raised their price target on Astrana Health from $30.00 to $41.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $49.43.

Astrana Health Price Performance

Astrana Health stock opened at $40.81 on Friday. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of 49.77 and a beta of 0.87. The stock has a fifty day simple moving average of $41.34 and a two-hundred day simple moving average of $32.87. Astrana Health has a 12 month low of $18.08 and a 12 month high of $51.60. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 1.05.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ASTH. Swiss National Bank grew its holdings in Astrana Health by 1.2% during the 3rd quarter. Swiss National Bank now owns 86,944 shares of the company’s stock valued at $2,465,000 after buying an additional 1,000 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Astrana Health by 5.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,768 shares of the company’s stock worth $799,000 after acquiring an additional 1,263 shares in the last quarter. Deutsche Bank AG raised its holdings in shares of Astrana Health by 3.9% during the 4th quarter. Deutsche Bank AG now owns 41,265 shares of the company’s stock worth $1,024,000 after acquiring an additional 1,550 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Astrana Health by 3.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 42,258 shares of the company’s stock valued at $1,049,000 after acquiring an additional 1,562 shares during the last quarter. Finally, Strs Ohio bought a new position in shares of Astrana Health during the 4th quarter valued at approximately $40,000. Hedge funds and other institutional investors own 52.77% of the company’s stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.